Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Mar;4(2):117–121. doi: 10.1128/cdli.4.2.117-121.1997

Improved reactivity of hepatitis C virus core protein epitopes in a conformational antigen-presenting system.

E Buratti 1, M Di Michele 1, P Song 1, C Monti-Bragadin 1, E A Scodeller 1, F E Baralle 1, S G Tisminetzky 1
PMCID: PMC170488  PMID: 9067642

Abstract

Recent studies have identified several epitopes in the N-terminal portion of the nucleocapsid protein which are predominantly recognized by sera of patients infected with hepatitis C virus (HCV). The characterization of the sequences recognized by theses antibodies and the evaluation of their reactivities have been performed mainly with synthetic peptides. However, synthetic peptides are notoriously unreliable as antigens when the immune response is directed against conformational epitopes. In order to improve the detection of antibody responses in HCV-infected patients, we have evaluated the reactivities of three immunodominant regions of the HCV core protein (residues 1 to 20, 21 to 40, and 32 to 46) displayed in a conformation-specific manner on the surface of the Flock House virus (FHV) capsid protein. The results obtained with these proteins in the analysis of 94 serum samples positive by anti-HCV enzyme-linked immunosorbent assay where then compared with those obtained with the corresponding synthetic peptides. The sequence most reactive both with the peptide and with the FHV protein was the region from residues 1 to 20, confirming the low conformational requirements for the display of these residues. On the other hand, the already reported conformational nature of residues 32 to 46 is in keeping with its observed high reactivity when displayed by the FHV recombinant protein and with the low reactivity displayed by its corresponding synthetic peptide. Finally, the high reactivity observed for the chimeric protein displaying the region from residues 21 to 40, as opposed to the results obtained with the synthetic peptide, also suggests that this sequence contains one or more conformational epitopes whose structures cannot be mimicked correctly with synthetic peptides.

Full Text

The Full Text of this article is available as a PDF (83.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blum P., Velligan M., Lin N., Matin A. DnaK-mediated alterations in human growth hormone protein inclusion bodies. Biotechnology (N Y) 1992 Mar;10(3):301–304. doi: 10.1038/nbt0392-301. [DOI] [PubMed] [Google Scholar]
  2. Buratti E., Tisminetzky S. G., Scodeller E. S., Baralle F. E. Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein. J Immunol Methods. 1996 Oct 16;197(1-2):7–18. doi: 10.1016/0022-1759(96)00097-x. [DOI] [PubMed] [Google Scholar]
  3. Cerino A., Boender P., La Monica N., Rosa C., Habets W., Mondelli M. U. A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol. 1993 Dec 15;151(12):7005–7015. [PubMed] [Google Scholar]
  4. Chien D. Y., Choo Q. L., Tabrizi A., Kuo C., McFarland J., Berger K., Lee C., Shuster J. R., Nguyen T., Moyer D. L. Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10011–10015. doi: 10.1073/pnas.89.21.10011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ching W. M., Wychowski C., Beach M. J., Wang H., Davies C. L., Carl M., Bradley D. W., Alter H. J., Feinstone S. M., Shih J. W. Interaction of immune sera with synthetic peptides corresponding to the structural protein region of hepatitis C virus. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3190–3194. doi: 10.1073/pnas.89.8.3190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  7. Choo Q. L., Richman K. H., Han J. H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby R., Barr P. J. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451–2455. doi: 10.1073/pnas.88.6.2451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Claeys H., Volckaerts A., De Beenhouwer H., Vermylen C. Association of hepatitis C virus carrier state with the occurrence of hepatitis C virus core antibodies. J Med Virol. 1992 Apr;36(4):259–264. doi: 10.1002/jmv.1890360405. [DOI] [PubMed] [Google Scholar]
  9. Ferroni P., Mascolo G., Zaninetti M., Colzani D., Pregliasco F., Pirisi M., Barbone F., Gasparini V. Identification of four epitopes in hepatitis C virus core protein. J Clin Microbiol. 1993 Jun;31(6):1586–1591. doi: 10.1128/jcm.31.6.1586-1591.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Goeser T., Müller H. M., Ye J., Pfaff E., Theilmann L. Characterization of antigenic determinants in the core antigen of the hepatitis C virus. Virology. 1994 Dec;205(2):462–469. doi: 10.1006/viro.1994.1666. [DOI] [PubMed] [Google Scholar]
  11. Houghton M., Weiner A., Han J., Kuo G., Choo Q. L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology. 1991 Aug;14(2):381–388. [PubMed] [Google Scholar]
  12. Katayama T., Mazda T., Kikuchi S., Harada S., Matsuura Y., Chiba J., Ohba H., Saito I., Miyamura T. Improved serodiagnosis of non-A, non-B hepatitis by an assay detecting antibody to hepatitis C virus core antigen. Hepatology. 1992 Mar;15(3):391–394. doi: 10.1002/hep.1840150306. [DOI] [PubMed] [Google Scholar]
  13. Kato N., Hijikata M., Ootsuyama Y., Nakagawa M., Ohkoshi S., Sugimura T., Shimotohno K. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9524–9528. doi: 10.1073/pnas.87.24.9524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Khanna A., Ray R. Hepatitis C virus core protein: synthesis, affinity purification and immunoreactivity with infected human sera. Gene. 1995 Feb 14;153(2):185–189. doi: 10.1016/0378-1119(94)00782-n. [DOI] [PubMed] [Google Scholar]
  15. Kuo G., Choo Q. L., Alter H. J., Gitnick G. L., Redeker A. G., Purcell R. H., Miyamura T., Dienstag J. L., Alter M. J., Stevens C. E. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989 Apr 21;244(4902):362–364. doi: 10.1126/science.2496467. [DOI] [PubMed] [Google Scholar]
  16. Miyamura T., Saito I., Katayama T., Kikuchi S., Tateda A., Houghton M., Choo Q. L., Kuo G. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci U S A. 1990 Feb;87(3):983–987. doi: 10.1073/pnas.87.3.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mohammad K., Esen A. A blocking agent and a blocking step are not needed in ELISA, immunostaining dot-blots and western blots. J Immunol Methods. 1989 Feb 8;117(1):141–145. doi: 10.1016/0022-1759(89)90129-4. [DOI] [PubMed] [Google Scholar]
  18. Moore J. P., Cao Y., Conley A. J., Wyatt R., Robinson J., Gorny M. K., Zolla-Pazner S., Ho D. D., Koup R. A. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. J Acquir Immune Defic Syndr. 1994 Apr;7(4):332–339. [PubMed] [Google Scholar]
  19. Moore J. P. The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. AIDS Res Hum Retroviruses. 1993 Mar;9(3):209–219. doi: 10.1089/aid.1993.9.209. [DOI] [PubMed] [Google Scholar]
  20. Nagayama R., Miyake K., Tsuda F., Okamoto H. IgM antibody to a hepatitis C virus core peptide (CP14) for monitoring activity of liver disease in patients with acute or chronic hepatitis C. J Med Virol. 1994 Mar;42(3):311–317. doi: 10.1002/jmv.1890420320. [DOI] [PubMed] [Google Scholar]
  21. Nasoff M. S., Zebedee S. L., Inchauspé G., Prince A. M. Identification of an immunodominant epitope within the capsid protein of hepatitis C virus. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5462–5466. doi: 10.1073/pnas.88.12.5462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nishizono A., Hiraga M., Mifune K., Terao H., Fujioka T., Nasu M., Goto T., Misumi J., Moriyama M., Arakawa Y. Correlation of serum antibody titers against hepatitis C virus core protein with clinical features by western blot (immunoblot) analysis using a recombinant vaccinia virus expression system. J Clin Microbiol. 1993 May;31(5):1173–1178. doi: 10.1128/jcm.31.5.1173-1178.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ohkoshi S., Watanabe M., Kuwana K., Tawaraya H., Kamimura T., Asakura H. Clinical evaluation of the antibody against core protein of hepatitis C virus. Gastroenterol Jpn. 1993 May;28 (Suppl 5):80–83. doi: 10.1007/BF02989212. [DOI] [PubMed] [Google Scholar]
  24. Saito M., Hasegawa A., Kashiwakuma T., Kohara M., Sugi M., Miki K., Yamamoto T., Mori H., Ohta Y., Tanaka E. Performance of an enzyme-linked immunosorbent assay system for antibodies to hepatitis C virus with two new antigens (c11/c7). Clin Chem. 1992 Dec;38(12):2434–2439. [PubMed] [Google Scholar]
  25. Schutten M., Langedijk J. P., Andeweg A. C., Huisman R. C., Meloen R. H., Osterhaus A. D. Characterization of a V3 domain-specific neutralizing human monoclonal antibody that preferentially recognizes non-syncytium-inducing human immunodeficiency virus type 1 strains. J Gen Virol. 1995 Jul;76(Pt 7):1665–1673. doi: 10.1099/0022-1317-76-7-1665. [DOI] [PubMed] [Google Scholar]
  26. Scodeller E. A., Tisminetzky S. G., Porro F., Schiappacassi M., De Rossi A., Chiecco-Bianchi L., Baralle F. E. A new epitope presenting system displays a HIV-1 V3 loop sequence and induces neutralizing antibodies. Vaccine. 1995 Sep;13(13):1233–1239. doi: 10.1016/0264-410x(95)00058-9. [DOI] [PubMed] [Google Scholar]
  27. Siemoneit K., da Silva Cardoso M., Wölpl A., Epple S., Wintersinger H., Koerner K., Kubanek B. Isotype-specific immune response to a single hepatitis C virus core epitope defined by a human monoclonal antibody: diagnostic value and correlation to PCR. Ann Hematol. 1994 Sep;69(3):129–133. doi: 10.1007/BF01695693. [DOI] [PubMed] [Google Scholar]
  28. Sällberg M., Pumpen P., Zhang Z. X., Lundholm P., Gusars I., Rudén U., Wahren B., Magnius L. O. Locations of antibody binding sites within conserved regions of the hepatitis C virus core protein. J Med Virol. 1994 May;43(1):62–68. doi: 10.1002/jmv.1890430112. [DOI] [PubMed] [Google Scholar]
  29. Takamizawa A., Mori C., Fuke I., Manabe S., Murakami S., Fujita J., Onishi E., Andoh T., Yoshida I., Okayama H. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol. 1991 Mar;65(3):1105–1113. doi: 10.1128/jvi.65.3.1105-1113.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tanaka E., Kiyosawa K., Nakatsuji Y., Inoue Y., Miyamura T., Chiba J., Furuta S. Clinical significance of antibodies to nonstructural and core proteins of hepatitis C virus in posttransfusion hepatitis patients during long-term follow-up. J Med Virol. 1993 Apr;39(4):318–324. doi: 10.1002/jmv.1890390411. [DOI] [PubMed] [Google Scholar]
  31. Tisminetzky S. G., Scodeller E. A., Evangelisti P., Chen Y., Schiappacassi M., Porro F., Bizik F., Zacchi T., Lunazzi G., Miertus S. Immunoreactivity of chimeric proteins carrying the HIV-1 epitope IGPGRAF. Correlation between predicted conformation and antigenicity. FEBS Lett. 1994 Oct 10;353(1):1–4. doi: 10.1016/0014-5793(94)00972-4. [DOI] [PubMed] [Google Scholar]
  32. Yeh C. T., Han C. M., Lo S. Y., Ou J. H., Fan K. D., Sheen I. S., Chu C. M., Liaw Y. F. Early detection of anti-HCc antibody in acute hepatitis C virus (HCV) by western blot (immunoblot) using a recombinant HCV core protein fragment. J Clin Microbiol. 1994 Sep;32(9):2235–2241. doi: 10.1128/jcm.32.9.2235-2241.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES